Comparison of Efficacy between Permethrin 5% Cream and Ivermectin 1% Cream in Combination with Oral Doxycycline in Treatment of Papulopustular Rosacea Patients

Document Type : Original Article (s)

Authors

1 Assistant Professor of Dermatology, Skin Diseases and Leishmaniasis Research Center, Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran

2 Professor of Dermatology, Skin Diseases and Leishmaniasis Research Center, Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran

3 Specialist in Dermatologist, Skin Diseases and Leishmaniasis Research Center, Department of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran

4 General Practitioner, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

5 MSc of Epidemiology, Cancer Prevention Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: This study aimed to compare the impact of 5% permethrin cream combined with oral doxycycline with 1% ivermectin cream combined with oral doxycycline in treating patients with papulopustular rosacea.
Methods: This study was a single-blind clinical trial on papulopustular rosacea patients at Isfahan teaching hospitals. Patients were randomly divided into two groups: one receiving 5% permethrin cream with oral doxycycline and the other receiving 1% ivermectin cream with oral doxycycline. Inflammatory lesion count, IGA Score, and VAS Score were compared at 0, 6, and 12-week intervals.
Findings: All 40 patients involved in the study were female, with an average age of 42.53 ± 10.4 years. The findings revealed a significant decrease in the average number of inflammatory lesions over time in both treatment groups (P < 0.05). Nevertheless, there was no notable variance in the number of inflammatory lesions over time between the two groups (P = 0.098). Additionally, the average IGA Score in both treatment cohorts significantly reduced as time progressed (P < 0.05). However, there was no significant contrast in IGA Score changes over time between the two treatment groups (P = 0.129). Patient satisfaction levels did not differ significantly between the two groups (P = 0.635).
Conclusion: The results indicated that both treatments were effective in decreasing the disease severity, reducing inflammatory lesions, and lowering the IGA Score. Nevertheless, no substantial superiority of one treatment over the other was observed in this study.

Highlights

Nazila Poostiyan: PubMed ,Google Scholar

Gita Faghihi: PubMed , Google Scholar

Setayesh Sindarreh: PubMed ,Google Scholar

Keywords

Main Subjects

References

  1. Napierkowski DB. Rosacea: Diagnosis and management. The Nurse Practitioner 2016; 41(4): 8-13.
  2. Tan J, Almeida LMC, Bewley A, Cribier B, Dlova NC, Gallo R, et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol 2017; 176(2): 431-8.
  3. Vieira ACC, Höfling-Lima AL, Mannis MJ. Ocular rosacea: a review. Arquivos brasileiros de oftalmologia 2012; 75(5): 363-9.
  4. Chernyshov P, Finlay A, Tomas‐Aragones L,
    Steinhoff M, Manolache L, Pustisek N, et al. Quality of life measurement in rosacea. Position statement of the European academy of dermatology and venereology task forces on quality of life and patient oriented outcomes and acne, rosacea and hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2023; 37(5): 954-64.
  5. Barakji YA, Rønnstad ATM, Christensen MO, Zachariae C, Wienholtz NK, Halling A-S, et al. Assessment of Frequency of Rosacea Subtypes in Patients With Rosacea: A Systematic Review and Meta-analysis. JAMA Dermatol 2022; 158(6): 617-25.
  6. Sharma A, Kroumpouzos G, Kassir M, Galadari H, Goren A, Grabbe S, et al. Rosacea management: a comprehensive review. J Cosmet Dermatol 2022; 21(5): 1895-904.
  7. Del Rosso JQ, Webster G, Weiss JS, Bhatia ND, Gold LS, Kircik L. Nonantibiotic properties of tetracyclines in rosacea and their clinical implications. J Clin Aesthet Dermatol 2021; 14(8): 14-21.
  8. Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield L, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents. Cutis 2013; 92(6): 277-84.
  9. Del Rosso J, Baldwin H, Bhatia N, Chavda R, York JP, Harper J, et al. A review of the Diagnostic and Therapeutic Gaps in Rosacea Management: Consensus Opinion. Dermatol Ther (Heidelb) 2024; 14(2): 271-84.
  10. Trave I, Micalizzi C, Cozzani E, Gasparini G, Parodi A. Papulopustular rosacea treated with ivermectin 1% cream: remission of the Demodex mite infestation over time and evaluation of clinical relapses. Dermatol Pract Concept 2022; 12(4): e2022201.
  11. Husein‐ElAhmed H, Steinhoff M. Efficacy of topical ivermectin and impact on quality of life in patients with papulopustular rosacea: a systematic review and meta‐ Dermatol Ther 2020; 33(1): e13203.
  12. Ebneyamin E, Mansouri P, Rajabi M, Qomi M, Asgharian R, Azizian Z. The efficacy and safety of permethrin 2.5% with tea tree oil gel on rosacea treatment: A double‐blind, controlled clinical trial. controlled clinical trial. J Cosmet Dermatol 2020; 19(6): 1426-31.
  13. Kocak M, Yagli S, Vahapoğlu G, Ekşioğlu M. Permethrin 5% Cream versus Metronidazole 0.75% Gel for the Treatment of Papulopustular RosaceaA Randomized Double-Blind Placebo-Controlled Study. Dermatology 2002; 205(3): 265-70.
  14. Raoufinejad K, Mansouri P, Rajabi M, Naraghi Z, Jebraeili R. Efficacy and safety of permethrin 5% topical gel vs. placebo for rosacea: a double‐blind randomized controlled clinical trial. J Eur Acad Dermatol Venereol 2016; 30(12): 2105-17.
  15. Aquilina C, Viraben R, Sire S. Ivermectin-responsive demodex infestation during human immunodeficiency virus infectiona case report and literature review. Dermatology 2002; 205(4): 394-7.
  16. Allen KJ, Davis CL, Billings SD, Mousdicas N. Recalcitrant papulopustular rosacea in an immunocompetent patient responding to combination therapy with oral ivermectin and topical permethrin. Cutis 2007; 80(2): 149-51.
  17. Forstinger C, Kittler H, Binder M. Treatment of rosacea-like demodicidosis with oral ivermectin and topical permethrin cream. J Am Acad Dermatol 1999; 41(5 Pt 1): 775-7.
  18. Chhaiya SB, Patel VJ, Dave JN, Mehta DS, Shah HA. Comparative efficacy and safety of topical permethrin, topical ivermectin, and oral ivermectin in patients of uncomplicated scabies. Indian J Dermatol Venereol Leprol 2012; 78(5): 605-10.
  19. Cardwell LA, Alinia H, Moradi Tuchayi S, Feldman SR. New developments in the treatment of rosacea–role of once-daily ivermectin cream. C Clin Cosmet Investig Dermatol 2016; 9: 71-7.
  20. Steinhoff M, Vocanson M, Voegel JJ, Hacini-Rachinel F, Schäfer G. Topical ivermectin 10 mg/g and oral doxycycline 40 mg modified-release: current evidence on the complementary use of anti-inflammatory rosacea treatments. Adv Ther 2016; 33(9): 1481-501.
Journal of Isfahan Medical School
Volume 42, Issue 759
3rd Week, May
May and June 2024
Pages 160-167

Files

History

  • Receive Date: 20 February 2024
  • Accept Date: 23 June 2024

Share

How to cite

Statistics